FORE Cancer Research

FORE Cancer Research was formed by Mark Thomas as a grass roots vehicle to help raise funds and awareness for cancer research. After losing his Aunt (Mary Bolte) to a long battle with ovarian cancer in the fall of 2006, her courage gave Mark the inspiration to try and make a difference.
Together with a group of friends and business associates, they organize and host a event to benefit cancer research at Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute. The Charity Pro-Am provides an opportunity for golfers of all skill levels, business leaders, philanthropists, friends and celebrities to team up for a great cause for a fun-filled, memorable event at a fantastic golf venue. Together we can make a difference and help put an end, once and for all, to this terrible disease.
The goal and only mission of FORE Cancer Research is to raise as much money as possible to support critical cancer research projects by some of the country’s leading doctors and scientists. By supporting cancer research you can ensure that innovation, greater understanding of the disease, discoveries and more effective cancer immunotherapies will continue.

After 7 years, FORE Cancer Research has raised $954,627 and funded cancer research projects targeting melanoma, breast, ovarian, colorectal, lung, soft tissue cancers and genomic sequencing of DNA & RNA. In 2014, FORE Cancer Research will exceed the $1 Million mark for cancer research donations.

Save The Date:
The 8th Annual FORE Cancer Research Charity Pro-Am

Monday, August 4, 2014
The Lakes Golf and Country Club
6740 Worthington Rd. Westerville, Ohio 43082

Give 18 FORE Cancer Research
If every golfer gives $18.00 per year to fund cancer research we can have a significant impact on a disease that affects all of us. We are asking you to give $18.00 once a year and help make a difference! Please consider a yearly donation of $18.00 and tell your friends, family and fellow golf enthusiasts to join us in our fight to beat cancer once and for all. Your donations will go directly to fund cancer research projects by the brightest Doctors, Scientists and Researchers at the nation’s leading cancer research facilities throughout the United States, including the OSUCCC - James. For more information and to Give 18, visit the FORE Cancer Research Give 18 website.

FORE is proud to have supported the following projects:
Genomic Sequencing of DNA and RNA (2012)- Sameek Roychowdhury, MD, PhD, Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
Dr. Roychowdhury is a physician scientist in medical oncology whose research asks “What is the right drug for my patient?” and “Why do previously effective drugs stop working?” Understanding how novel molecularly targeted drugs work or fail helps determine rational drug combination. The strategy is to simultaneously target separate weak points in cancer so that the disease cannot escape one drug. Similarly, the majority of drugs in development for cancer are so called smart drugs that target specific genetic mutations in cancer. Thus for patients who fail standard therapies, we will match their cancer with smart drugs in clinical trials. The lab runs a clinical study entitled “Personalized Oncology Through High-Throughput Sequencing” which evaluates individual patients with advanced cancer considering clinical trials and seeks to identify “driving” mutations that match novel molecularly targeted therapies in development. To do this, they use cutting edge genome sequencing technologies, also known as next generation sequencing or massively parallel sequencing. This enables them to look deeply into the molecular or genetic alterations that occur in an individual’s cancer. Thereafter, they will match patients based on mutations found in their cancer to clinical trials with corresponding smart drugs. Through support from the Fore Cancer Research Foundation, we will develop the genomic diagnostic tools for testing patients with advanced cancer. This process entails 1) genomic sequencing of DNA and RNA, 2) bioinformatics (computer) analysis of the genes, 3) experimental determination of genes involved in drug resistance, 4) co-development of clinical trials for molecularly targeted therapies (smart drugs) including inhibitors of BRAF, PI3kinase, fibroblast growth factor receptor (FGFR), and cyclin-dependent kinase (CDK).

Genetic Cancer Research Fund (2011)- Dr. Goldberg - The Ohio State University

Each year, 6,026 Ohioans are diagnosed with colorectal cancer. Lynch syndrome is the most common hereditary cause of colorectal and endometrial cancer. Previous work done at the James by Dr. Albert de la Chapelle and Heather Hampel, MS, CGC has shown that 1 out of every 35 colorectal cancer patients and in 1 out of every 40 endometrial cancer patients has Lynch syndrome. In addition, many of their relatives will also have Lynch syndrome and very high risks for cancer. There is evidence that early cancer surveillance and prevention strategies can prevent cancers and save lives in these high risk individuals. The current study plans to test approximately 4,000 colorectal cancer patients in Ohio to prove that this screening can be done on a large scale basis and to determine the best approach to doing this screening so that it can be implemented nationally. It is calculated that a minimum of 120 of these patients and 360 of their relatives will have LS. As a result, 480 individuals will be diagnosed with Lynch syndrome as part of this study and will be able to benefit from appropriate medical management. Dr. Goldberg will be involved in developing therapeutic studies for the colorectal cancer patients that are found to be more likely to have Lynch syndrome (800) and in the identification of new colorectal cancer genes.

Pre-clinical and Clinical studies of Combination HER-2 /neu (2009/2010)-  Pravin T. P Kaumaya, PhD - The Ohio State University
The American Cancer Society estimates that 21,550 new cases of ovarian will be diagnosed in the US in 2009 with 14,600 deaths predicted. Of 192,370 newly diagnosed breast cancer patients, some 40,170 people will die from the disease. Ovarian Cancer is the second most common gynecologic cancer, with an incidence of about 15 cases per 100,000 women in western countries, and approximately 250,000 new cases and 125,00 deaths worldwide annually.
The NCI Strategic plan to defeat Cancer by 2015 is in tune with the Comprehensive Cancer Center goals: To improve people’s lives through innovation in research, education and patient care. Thus, the goals of developing “effective treatments to treat malignancy by either destroying all cancer cells or modulating and controlling metastases both with minimal harm to healthy tissue” mean integrating preclinical and clinical research and to translating research into high-quality patient care for residents of central Ohio and beyond. That means developing novel prophylactic as well as therapeutic vaccines and treatments. Stimulating the immune system to destroy tumor cells has long been a hope, and the realization of this dream is beginning to show signs of success.
Discovery of a K-Ras Inhibitor for the Treatment of Lung Cancer in Women (2008)- Dr. Roger Briesewitz/Dr. Miguel Villalona/Dr. Dehua Pei - The Ohio State University
Lung cancer is the second most common malignancy in women after breast cancer1. Although breast cancer is more prevalent, lung cancer is the leading cause of cancer mortality in women, accounting for 26% of all cancer deaths1. Over the last 30 years, the incidence of lung cancer in women has increased fourfold1. This dramatic increase has been labeled a “contemporary epidemic” 2. Much of the dramatic increase in lung cancer observed in women appears to be based on the fact that women began to smoke cigarettes in increasing numbers starting in the 1940s and peaking in the 1970s. Despite the adverse risk effect of smoking, lung cancer may also develop in men and women who have never smoked. Compared to men, women in fact appear to be at a higher risk of developing lung cancer, suggesting sex-specific differences that promote the development of the disease3.
Our current therapeutic options for the treatment of lung cancer are very limited. 72% of all women diagnosed with lung cancer will eventually succumb to the disease despite treatment1. Novel therapeutic approaches are desperately needed to improve the odds of survival. In recent years we have gained important insights into the underlying genetic aberrations that cause lung cancer. Based on these insights we may be able to develop targeted therapeutics that are directed against the cancer cells and that, ideally, have only limited detrimental effects on healthy cells. 
The Role of microRNA in the Progression of Malignant Melanoma (2007)- Gregory B. Lesinski, Ph.D. - The Ohio State University
"We are investigating whether small nucleic acid sequences, called microRNA can serve as markers to predict whether ‘borderline’ skin lesions will develop into melanoma, the most deadly form of skin cancer. Our preliminary research has shown that two specific microRNA sequences (microRNA-21 and microRNA-155) are more prevalent in biopsies from patients with melanoma when compared to patients with benign, non-cancerous biopsies. We will determine whether microRNA-21 and microRNA-155 make melanoma cells more aggressive and determine if the level of mircoRNA can predict whether borderline skin lesions become cancerous."


The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: